Singular Genomics Systems 超出了 2023 年第四季度的盈利预期，报告每股收益为-0.32 美元，收入为 108 万美元。 Singular Genomics Systems beat Q4 2023 earnings expectations, reporting EPS of $-0.32 and $1.08M revenue.
Singular Genomics Systems, Inc.（纳斯达克股票代码：OMIC）超出了 2023 年第四季度的盈利预期，报告每股收益为-0.32 美元，而预期为-0.34 美元。 Singular Genomics Systems, Inc. (NASDAQ: OMIC) beat Q4 2023 earnings expectations, reporting EPS of $-0.32 compared to expected $-0.34. 该公司的收入为 108 万美元。 The company's revenue was $1.08M. 尽管如此，OMIC 并未跻身 2023 年第三季度末最受欢迎的 30 只对冲基金股票之列。 Despite this, OMIC was not among the 30 most popular hedge fund stocks at the end of Q3 2023. 高盛集团将该公司的目标股价从 0.95 美元下调至 0.85 美元，维持“中性”评级。 Goldman Sachs Group lowered its price objective on the company from $0.95 to $0.85, maintaining a "neutral" rating.